Targeting AXL were shown to sensitize tumours to various types of therapies, including DNA damaging agents, EGFR, VEGFR, HDAC, G2/M checkpoint, and immune checkpoint inhibitors (Table 1). This evidence concerns the gene AXL and neoplasm.